SCHEMBL6072322

SCHEMBL6072322

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1ccc(C(=O)O)c(NCCC(C)=O)c1)=NC(C)(C)C2

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.32
IDO1 P14902 1/20 0.31
FFAR4 Q5NUL3 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071900 0.93 TDP1 (0.32) PDE10AFFAR4
Hydrochloric Acid SCHEMBL6071848 0.92 TDP1 (0.31) PDE10AFFAR4
SCHEMBL6072284 0.91 IDO1 (0.33) IDO1FFAR4
SCHEMBL6071815 0.90 SMN1; SMN2 (0.34) IDO1
SCHEMBL6072762 0.90 IDO1 (0.32) IDO1FFAR4
SCHEMBL6072196 0.88 HSD17B10 (0.36) IDO1
SCHEMBL6072657 0.88 MAPT (0.33) PDE10AIDO1
SCHEMBL6072191 0.88 ACLY (0.38) IDO1
SCHEMBL6072317 0.87 IDO1 (0.31) IDO1
SCHEMBL6072777 0.87 AKR1C3 (0.35) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A PDE10A 20/4885IDO1 1813/4885FFAR4 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.